This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubinow, A. Articles by Cohen, A. S. Search for Related Content PubMed PubMed Citation Articles by Rubinow, A. Articles by Cohen, A. S.

Circulation, Vol 63, 1285-1288, Copyright © 1981 by American Heart Association

ARTICLES

Digoxin sensitivity in amyloid cardiomyopathy

A Rubinow, M Skinner and AS Cohen

Digoxin (5 mg/ml) was added to 10-mg and 20-mg pellets of purified primary and secondary amyloid fibrils, a normal human liver and heart homogenate and a homogenate from the heart of a patient with amyloid cardiomyopathy who had not received digitalis. After centrifugation, the supernatants were recovered and assayed for digoxin concentrations. Aliquots from the sediments were studied for the presence of digoxin, using rabbits antidigoxin antiserum and an indirect immunofluorescent technique. The results showed that 0.11--0.13 ng/ml of digoxin bound per milligram of fibrils and could not be separated by repeated washings. Elution with citrate or changes in the pH of the buffer. Immunofluorescent studies demonstrated diffusely bright immunofluorescence with the fibril preparation and amyloid heart homogenate when reacted with digoxin and digoxin-specific antiserum. These studies demonstrate that isolated amyloid fibrils bind digoxin and suggest that this interaction may play some role in the sensitivity to digitalis that has been observed in some patients with amyloid cardiomyopathy.

This article has been cited by other articles:

				J. B. Selvanayagam, P. N. Hawkins, B. Paul, S. G. Myerson, and S. Neubauer Evaluation and Management of the Cardiac Amyloidosis J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2101 - 2110. [Abstract] [Full Text] [PDF]

				K. B. Shah, Y. Inoue, and M. R. Mehra Amyloidosis and the heart: a comprehensive review. Arch Intern Med, September 25, 2006; 166(17): 1805 - 1813. [Abstract] [Full Text] [PDF]

				J. Buxbaum, D. R. Jacobson, C. Tagoe, A. Alexander, D. W. Kitzman, B. Greenberg, S. Thaneemit-Chen, and P. Lavori Transthyretin V122I in African Americans With Congestive Heart Failure J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1724 - 1725. [Full Text] [PDF]

				R. H. Falk Diagnosis and Management of the Cardiac Amyloidoses Circulation, September 27, 2005; 112(13): 2047 - 2060. [Full Text] [PDF]

				M F Khan and R H Falk Amyloidosis Postgrad. Med. J., November 1, 2001; 77(913): 686 - 693. [Abstract] [Full Text] [PDF]

				J D Gillmore, D R Booth, M B Pepys, and P N Hawkins Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man Heart, September 1, 1999; 82 (3): e2 - e2. [Abstract] [Full Text] [PDF]

				R. H. Falk, R. L. Comenzo, and M. Skinner The Systemic Amyloidoses N. Engl. J. Med., September 25, 1997; 337(13): 898 - 909. [Full Text] [PDF]

				D. R. Jacobson, R. D. Pastore, R. Yaghoubian, I. Kane, G. Gallo, F. S. Buck, and J. N. Buxbaum Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans N. Engl. J. Med., February 13, 1997; 336(7): 466 - 473. [Abstract] [Full Text] [PDF]